Abstract Sickle Cell Disease (SCD) is one of the most inherited hematologic diseases
affecting humans. Clinically, there is a progressive multiorgan failure and increased mortality …

Sickle cell disease (SCD) is the most common hemoglobinopathy worldwide, characterized
by vaso-occlusive crises and ischemia that affects patients on a multi-system level. Despite …

The COVID-19 pandemic has created major disruptions in health care delivery, including a
severe blood shortage. The inventory of Rh and K antigen–negative red cell units …

Red blood cell (RBC) transfusion is an essential treatment for many patients with sickle cell
disease (SCD), whose RBCs express hemoglobin S (HbS), a mutated form of hemoglobin A …

Background With chronic transfusion in sickle cell disease (SCD), equipoise exists
regarding whether increasing the post‐procedure hematocrit (Hct) suppresses endogenous …

Sickle cell disease (SCD) is associated with significant morbidity and mortality, and limits
both the quality and quantity of life. Transfusion therapy, specifically automated red cell …

Background Due to the national blood supply crisis caused by the COVID‐19 pandemic, the
American Society of Hematology proposed guidance to decrease blood utilization for sickle …

Sickle cell disease (SCD), the most common hemoglobinopathy worldwide after
thalassemia, is characterized by a mutation in the β-globin gene that results in the …

Background Chronic automated red cell exchange (RCE) is increasingly employed for sickle
cell disease (SCD). There is a paucity of data on the incidence of RCE adverse events (AEs) …

Background Adequate CD34+ collection efficiency (CE) is critical to achieve target CD34+
cell doses in hematopoietic progenitor cell (HPC) collections. Autologous HPC collection in …